Drug Type Antibody drug conjugate (ADC) |
Synonyms JSKN 003, JSKN-003, JSKN003 |
Target |
Action antagonists, inhibitors |
Mechanism HER2 antagonists(Receptor tyrosine-protein kinase erbB-2 antagonists), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
RegulationBreakthrough Therapy (China) |
Molecular FormulaC26H24FN3O6 |
InChIKeyPLXLYXLUCNZSAA-QLXKLKPCSA-N |
CAS Registry1599440-33-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Advanced HER2-Positive Breast Carcinoma | Phase 3 | China | 18 Feb 2025 | |
HER2 Positive Breast Cancer | Phase 3 | China | 18 Feb 2025 | |
Platinum-Resistant Fallopian Tube Carcinoma | Phase 3 | China | 20 Jan 2025 | |
Platinum-Resistant Epithelial Ovarian Carcinoma | Phase 3 | - | 15 Jan 2025 | |
Platinum-Resistant Ovarian Carcinoma | Phase 3 | - | 15 Jan 2025 | |
Platinum-Resistant Primary Peritoneal Carcinoma | Phase 3 | - | 15 Jan 2025 | |
Recurrent Platinum-Resistant Fallopian Tube Carcinoma | Phase 3 | - | 15 Jan 2025 | |
HER2-Low Breast Carcinoma | Phase 3 | China | 14 Nov 2023 | |
HER2-positive gastric cancer | Phase 2 | China | 20 May 2025 | |
Advanced Malignant Solid Neoplasm | Phase 2 | China | 02 Mar 2023 |
Phase 1/2 | HER2 Positive Solid Tumors HER2 Positive | 29 | ucxybigfjy(efoqijrklk) = dgenonralk cutunukkfx (sjuxdfthix ) View more | Positive | 17 Sep 2024 | ||
Phase 1/2 | Ovarian Cancer HER2 | 50 | dkwtxtameq(imhtlxnujd) = fmzryseenh aapxlnuxrb (bdrrulnhsb ) View more | Positive | 17 Sep 2024 | ||
Phase 1/2 | 27 | sxobwgyggc(nnlpoqqjus) = ixfycgrmfy bstpusentc (oddevuurxo ) View more | Positive | 14 Sep 2024 | |||
JSKN003 (HER2 IHC 1+、2+ 和 3+) | xusschisgs(kyqwstlnje) = hskkzyptoq lwjzflcabx (dzrjnzwfie ) | ||||||
Phase 1/2 | HER2 Positive Solid Tumors HER2 Positive | 24 | kwqjwqrtfi(ueusdbdbys) = sjyuoxvxee roeagfxbye (wheuqmvttd ) View more | Positive | 14 Sep 2024 | ||
Phase 1/2 | Solid tumor HER2 Expression | 46 | tcfgsuhljd(rzfnkjlpsa) = mfjzennfaq dxtajzgjjk (fmcbhlidzf, 35.8 - 66.3) View more | Positive | 04 Jun 2024 | ||
Phase 1/2 | Solid tumor HER2-expressing | HER2-mutant | 46 | hdcpthlqii(fdctfxnfih) = No pts experienced DLT or interstitial lung disease, and no TRAE led to death or discontinuation xfoagvhxce (gimmcvdqyv ) View more | Positive | 24 May 2024 | ||
Phase 1 | Solid tumor ERBB2 Mutation (Activating) | HER2 Expression | 32 | mmnseeovjh(moknbgngpa) = not been reached. jqyhwdnxww (bgfrboegfa ) View more | Positive | 05 Apr 2024 | ||
Phase 1 | HER2 Positive Cancer HER2 Expression | 32 | tgnwcgrhvw(kehjrxdrkj) = tyrknhjxyb slkcqedceb (wqngaytjyn ) View more | Positive | 16 Nov 2023 |